I-01 Jae Eun Ahn Modelling and Simulation of Motor Symptom Measurements in Parkinson’s Disease after L-Dopa Administration Wednesday 10:45-12:15 |
I-02 Mona Alameddine Optimal phase 2 dose selection based on the relationship between exposure and target occupancy Wednesday 10:45-12:15 |
I-24 Irina Bondareva Population modeling of changes in steady–state pharmacokinetics of carbamazepine (CBZ) due to antiepileptic drug-drug interactions from therapeutic drug monitoring (TDM) data Wednesday 10:45-12:15 |
I-34 Simon Buatois Using Item response theory to yield information from the MDS-UPDRS items in Parkinson’s disease clinical trials Wednesday 10:45-12:15 |
I-67 Sjoerd De Hoogd Population pharmacokinetics of morphine and its metabolites M3G and M6G in morbidly obese patients and healthy volunteers Wednesday 10:45-12:15 |
II-04 Rik Schoemaker PK/PD modeling of brivaracetam in epilepsy using daily seizure counts Wednesday 15:15-16:40 |
II-26 Eva Sverrisdottir Modelling drug-drug interactions between morphine and methylnaltrexone Wednesday 15:15-16:40 |
II-31 Paulo Teixeira Population Pharmacokinetics of Phenobarbital in Children, Adolescents and Young Adults Patients. Wednesday 15:15-16:40 |
II-45 Sven van Dijkman Optimal dosing recommendations for combination therapy in epilepsy Wednesday 15:15-16:40 |
III-11 Gregory Ferl Mechanistic model of amyloid beta and anti-amyloid beta mAb dynamics Thursday 10:20-11:45 |
III-30 Jinju Guk Model-based assessment of risks and benefits of tissue plasminogen activator treatment in acute ischemic stroke Thursday 10:20-11:45 |
III-36 Jacqueline Hannam A model for the respiratory effects of remifentanil and propofol during sedation and analgesia Thursday 10:20-11:45 |
III-45 Xiao Hu Exposure-Response Analysis of Peginterferon Beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis Thursday 10:20-11:45 |
III-54 Åsa Kragh Application of an Item Response Theory model to describe Amyotrophic Lateral Sclerosis Functional Rating Scale data Thursday 10:20-11:45 |
III-56 Niclas Jonsson Population Pharmacokinetic Simulations of Two Paliperidone Palmitate Formulations Thursday 10:20-11:45 |
III-58 Marija Jovanovic Nonlinear mixed effects modelling approach in investigating amitriptyline pharmacokinetics Thursday 10:20-11:45 |
III-60 Rasmus Juul Kildemoes Exploring the relationship between analgesic event rate and pain intensity in kidney stone surgery: A Repeated Time to Event Pilot Study Thursday 10:20-11:45 |
III-70 Julia Korell A population pharmacokinetic model for aripiprazole and dehydro-aripiprazole Thursday 10:20-11:45 |
IV-01 Joomi Lee Population pharmacokinetic modeling and simulation of moxifloxacin in human aqueous humor after topical ocular application Thursday 15:20-16:40 |
IV-05 Andreas Lindauer A two-part mixed-effects model for semi-continuous data to describe the effect of transdermal rotigotine on restless legs symptoms in adults Thursday 15:20-16:40 |
IV-11 Mats Magnusson Population Pharmacokinetic Modeling of Paliperidone Palmitate 3-Month Formulation Thursday 15:20-16:40 |
IV-41 Sean Oosterholt Population pharmacokinetics of NNZ-2566 in healthy subjects and Rett syndrome patients Thursday 15:20-16:40 |
IV-42 Fernando Ortega Modelling Amyloid- ß levels in the presence of a gamma-secretase inhibitor Thursday 15:20-16:40 |
IV-44 Theodoros Papathanasiou Response surface analysis of synergistic interactions of morphine and gabapentin in a rat model of postoperative pain. Thursday 15:20-16:40 |
IV-71 Alberto Russu Modelling pharmacokinetics and CSF Abeta1-40 reduction in humans after dosing with JNJ-54861911, a novel oral BACE inhibitor Thursday 15:20-16:40 |